Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ecs Botanics Holdings Ltd ( (AU:ECS) ) just unveiled an announcement.
ECS Botanics Holdings reported a second consecutive cash flow positive quarter, generating A$218,000 in operating cash for Q2 FY26, a turnaround of A$1.5 million versus the prior year’s December quarter, on revenue of A$5.65 million, up 19% year-on-year. The company’s branded B2C portfolio now contributes 65% of revenue after a 16% quarter-on-quarter rise in direct-to-consumer sales, supported by new product launches such as OzSun sugar-free THC gummies and preparations for the AVANI AVA women’s health range, helping offset ongoing wholesale price pressure in the domestic market. ECS also completed a A$1.95 million placement to fund product registrations, inventory build and European expansion, and ended the quarter with A$5 million in cash and available finance, giving it balance sheet flexibility to pursue growth despite intensifying competition and price compression in the medicinal cannabis sector.
More about Ecs Botanics Holdings Ltd
ECS Botanics Holdings Ltd is an ASX-listed medicinal cannabis company that has transitioned from a wholesale-focused model to a B2C-led strategy, selling its own branded, higher-margin finished dose products direct to consumers. The company operates primarily in the Australian medicinal cannabis market with growing international ambitions, and focuses on product innovation and diversification to mitigate domestic price compression from imports and local competition.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$9.58M
See more data about ECS stock on TipRanks’ Stock Analysis page.